12:00 AM
 | 
Dec 13, 2010
 |  BioCentury  |  Product Development

1-2-3, spe-cifi-city

Pfizer's axitinib improves PFS vs. Nexavar from Bayer/Onyx in RCC

One byproduct of recent development successes in metastatic renal cell carcinoma has been the emergence of questions about how best to use the various drugs. A variety of head-to-head studies are underway, and the first direct comparison of targeted agents was provided last month by Pfizer Inc., which reported axitinib met the primary endpoint of a Phase III trial, significantly improved progression-free survival vs. Nexavar sorafenib in second-line RCC.

Pfizer did not disclose detailed data on the pan-VEGF receptor tyrosine kinase inhibitor (TKI) because it plans to present the results at a scientific meeting in 1H11.

Glen Andrews, an asset team leader in Pfizer's oncology business unit, told BioCentury the company used a structure-based approach to create axitinib's binding profile, which he believes may provide advantages over TKIs marketed for RCC. These include Nexavar from Bayer AG and Onyx Pharmaceuticals Inc., Pfizer's own Sutent sunitinib and Votrient pazopanib from GlaxoSmithKline plc.

"Axitinib was designed as a selective and potent inhibitor of VEGF receptors 1, 2 and 3 because we believed that by targeting all three pathways we could have a better outcome," said Andrews. The compound also blocks platelet derived growth factor receptor (PDGFR) and stem cell factor receptor tyrosine kinase (c-Kit; KIT; CD117), albeit to...

Read the full 1068 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >